Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
暂无分享,去创建一个
Kai Fu | Xiaohong Zhao | Tint Lwin | Rekha Rao | Jianguo Tao | K. Fu | K. Bhalla | S. Chen‐Kiang | K. Wright | W. Dalton | E. Seto | L. Moscinski | J. Tao | V. Marquez | Xiaohong Zhao | T. Lwin | E. Sotomayor | William S Dalton | Yizhuo Zhang | Victor E Marquez | Edward Seto | Jianhong Lin | Kapil Bhalla | Jianhong Lin | Selina Chen-Kiang | W. Fiskus | Eduardo Sotomayor | Xinwei Zhang | Lynn C Moscinski | Kenneth L Wright | Rekha Rao | Warren Fiskus | Yizhuo Zhang | Xinwei Zhang | John C Chan | J. C. Chan
[1] Tint Lwin,et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. , 2010, Blood.
[2] J. Hsieh,et al. Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer* , 2005, Journal of Biological Chemistry.
[3] Bin Tean Teh,et al. Somatic mutations of the histone H3K27 demethylase, UTX, in human cancer , 2009, Nature Genetics.
[4] J. Pollack,et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. , 2008, Blood.
[5] G. Gores,et al. mir-29 regulates Mcl-1 protein expression and apoptosis , 2007, Oncogene.
[6] R. Willemze,et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma , 2001, British journal of haematology.
[7] R. Gascoyne,et al. MYC and Aggressive B-cell Lymphomas , 2011, Advances in anatomic pathology.
[8] Tsung-Cheng Chang,et al. Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.
[9] G. Neri,et al. Faculty Opinions recommendation of Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. , 2009 .
[10] Huidong Shi,et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. , 2009, Blood.
[11] A. Rosenwald,et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Meijer,et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. , 2001, Blood.
[13] M. Caligiuri,et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. , 2010, Cancer cell.
[14] Kathryn A. O’Donnell,et al. Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.
[15] W. Tansey,et al. Myc-mediated transcriptional repression by recruitment of histone deacetylase. , 2008, Cancer research.
[16] C. Croce,et al. Role of microRNAs in lymphoid biology and disease , 2011, Current opinion in hematology.
[17] Lu Wang,et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. , 2011, Cancer research.
[18] Y. Pekarsky,et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. , 2006, Cancer research.
[19] X. Zhang,et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas , 2012, Oncogene.
[20] K. Kang,et al. DNA Methyltransferase Controls Stem Cell Aging by Regulating BMI1 and EZH2 through MicroRNAs , 2011, PloS one.
[21] Anke Sparmann,et al. Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.
[22] Richard Simon,et al. Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.
[23] C. Morrison,et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.
[24] John L Cleveland,et al. Myc pathways provoking cell suicide and cancer , 2003, Oncogene.